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OBJECTIVEdTo examine the global prevalence and major risk factors for diabetic retino-
pathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes.
RESEARCHDESIGNANDMETHODSdA pooled analysis using individual participant
data from population-based studies around the world was performed. A systematic literature
review was conducted to identify all population-based studies in general populations or indi-
viduals with diabetes who had ascertained DR from retinal photographs. Studies provided data
for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and
also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to
the 2010 World Diabetes Population aged 20–79 years.
RESULTSdA total of 35 studies (1980–2008) provided data from 22,896 individuals with
diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04)
for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for
VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and
blood pressure levels and were higher in people with type 1 compared with type 2 diabetes.
CONCLUSIONSdThere are approximately 93 million people with DR, 17 million with
proliferative DR, 21million with diabetic macular edema, and 28million with VTDR worldwide.
Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated
with DR. These data highlight the substantial worldwide public health burden of DR and the
importance of modifiable risk factors in its occurrence. This study is limited by data pooled from
studies at different time points, with different methodologies and population characteristics.
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D iabetic retinopathy (DR) is the lead-ing causeof blindness amongworking-aged adults around the world (1).
Despite the significance of this problem,
and the rising prevalence of diabetes no-
tably in emerging Asian countries such
as India and China (2,3), there are few
precise contemporary estimates of the
worldwide prevalence of DR, particularly
severe vision-threatening stages of the dis-
ease, including proliferative DR (PDR) and
diabetic macular edema (DME).
Previous individual studies have
shown considerable variability in DR
prevalence estimates among individuals
with both diagnosed and undiagnosed
diabetes, with rates ranging from 17.6%
in a study in India (4) to 33.2% in a large
U.S. study (5). Differences in study meth-
odologies, population characteristics, and
ascertainment and classification of DR
have made direct comparisons between
studies difficult. A meta-analysis summa-
rized the U.S. prevalence of DR (6), but
this study was limited to individuals with
type 2 diabetes aged 40 years and older,
and the data were largely derived from
individuals of Caucasian background,
with limited data on other racial groups.
More important, this study did not in-
clude Asians, and an estimated 100 mil-
lion people in China and 80 million in
India have diabetes (2,3).
Although the major risk factors for
DR (e.g., hyperglycemia, hypertension,
dyslipidemia) have been examined in
many epidemiologic studies and clinical
trials (1), there is considerable variation in
the consistency, pattern, and strength of
these risk factors. This is particularly so
with respect to severe stages of DR, be-
cause individual studies generally lack
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power to detect significant associations
for PDR and DME. Thus, the importance
of modifiable risk factors for these vision-
threatening stages of DR remains unclear.
Generating a broader and more pre-
cise estimate of the prevalence of DR and
its relationship withmajormodifiable risk
factors, specifically for vision-threatening
DR (VTDR), is crucial for guiding public
health education and optimal clinical man-
agement of diabetes. We therefore con-
ducted an individual participant analysis
pooling population-based studies from the
U.S., Australia, Europe, and Asia to de-
termine the prevalence of DR and its
sight-threatening end points (PDR and
DME) as well as their relationship to key
risk factors.
RESEARCH DESIGN AND
METHODS
Study selection and
inclusion criteria
We first performed a systematic literature
review to identify all population-based
studies that had ascertained DR from
fundus (retinal) photographs. English-
language articles were retrieved using
Medline, EMBASE, Current Contents,
EBSCO, JSTOR, and Science Direct using
the following search terms: “diabetes” and
“retinopathy” or “diabetic macular
edema” and “population.” We identified
3,539 citations identified to 10 February
2010. Irrelevant and duplicate citations
were excluded after a review of the titles
and abstracts. The full texts of the remain-
ing articles were reviewed to ensure stud-
ies met inclusion and exclusion criteria.
In addition, we manually reviewed bib-
liographies of included articles and con-
sulted with colleagues to identify other
potentially relevant population-based
studies that had assessed DR from fundus
photographs but which may not have
published results or in which grading for
DR was still ongoing.
Studies were excluded if they were
not population-based and/or if fundus
photographs were not undertaken to
ascertain DR. Two investigators ( J.Y.,
R.Kaw.) independently selected the studies
for inclusion. Disagreements between the
two were resolved by adjudication with
two additional reviewers (S.R., T.Y.W.).
We identified 58 population-based
studies in which fundus photographs
were potentially assessed for DR. Princi-
pal investigators of these identified stud-
ies were then invited for collaboration in
this individual participant meta-analysis.
We requested individual participant data
regarding presence and severity of DR,
DME status, age, sex, ethnicity, diabetes
type and duration, hemoglobin A1c
(HbA1c), systolic and diastolic blood pres-
sure, lipid profile, cigarette smoking sta-
tus, BMI, and current use of diabetes,
antihypertensive, and lipid-lowering
medications.
Investigators from 35 of the 58 iden-
tified studies provided data for this analysis
(Table 1). Investigators of the remaining 23
studies could not or did not want to partic-
ipate, or did not respond to repeated invi-
tations. All studies had institutional board
review approval and provided appropri-
ately deidentified data for analysis.
DR assessment and definition
Retinal photography was performed in
all 35 studies according to standardized
protocols. Most of the studies graded for
DR using the Early Treatment Diabetic
Retinopathy Scale (ETDRS) and its mod-
ification or the American Academy of
Ophthalmology (AAO) International
Clinical Diabetic Retinopathy Disease Se-
verity Scale (Table 1).
DR severity was categorized as non-
PDR (NPDR; level 20 through level 53)
and PDR (level$60). DMEwas defined as
absent or present. The four primary out-
comes for this study were based on the
severity in the worse eye or of the single
eye that was photographed. Any DR was
defined as the presence of NPDR, PDR,
DME, or any combination thereof; and
VTDR was defined as the presence of
PDR and/or DME. These composite out-
comes serve as the primary outcomes for
this report, which respectively, indicate
presence of any DR and severe DR likely
to result in vision loss if left untreated.
Definition of diabetes and major
risk factors
Not all studies reported information on
diabetes type. If data on age at diagnosis of
diabetes were available in these studies,
participants were classified as type 1 if
they were diagnosed before age 30 years
and as type 2 if they were diagnosed with
diabetes after age 30 years, as previously
used in one study (7). Hypertension was
defined in subjects with a blood pressure
.140/90 or who reported being on treat-
ment for hypertension. Serum cholesterol
was categorized into levels ,4.0 or$4.0
mmol/L.
Appraisal of study methodology
and heterogeneity
Study methodology and heterogeneity
were assessed independently by two inves-
tigators ( J.Y., R.Kaw.). Any disagreement
was settled by consensus or adjudication
with a third reviewer (S.R.). Studies were
assessed for a list of attributes as defined
in Supplementary Table 1. Studies with
similar methodologies and rigorous
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Global prevalence and risk factors of DR
ophthalmologic definitions were defined as
those with a score of$9 (maximum, 11).
Statistical analysis
Data from each study were checked for
consistency in variable definition before
pooling, and where appropriate, data
were recategorized according to a common
definition. Race/ethnicity was categorized
as Caucasian (Europeans and those of
European origin), Asian (Chinese, Chinese
American, Japanese, Malay, Indian, or peo-
ple of Asian origin), African American, and
Hispanic (Mexican Americans). Asians
were further subdivided into Chinese or
Japanese origin, and South Asian (Indian,
Malay, South Indian, Thai, etc). Study-
specific and pooled-data estimates of the
prevalence of any DR, PDR, DME, and
VTDR were directly age-standardized to
the 2010 world diabetes population aged
20–79 years (8) using age strata 20–39,
40–59, and 60–79 years. We calculated
95% CIs for standardized prevalence
rates using a normal approximation and
Breslow-Day standard errors, after being
modified to use a binomial assumption
for the variance of the crude stratum-specific
rates (9).
Initial analyses included data from all
35 studies, and subsequent analyses were
performed using only data from studies
with similar methodologies and outcome
definitions (i.e., studies with a score of
$9). Results from the latter analyses are
presented throughout this report because
of their similar methodologies.
Poisson regression models with ro-
bust error variance were used to estimate
relative risks for DR, PDR, DME, and
VTDR by categories of risk factors (e.g.,
hypertension, duration), adjusting for age
(continuous, from 20–79 years), race
(five categories), hypertension (yes/no),
HbA1c (four categories) and study, as ap-
propriate. We also performed supple-
mentary analyses on the interaction
between diabetes type and duration, us-
ing people with type 2 diabetes for ,10
years as the reference group. Including
sex in regression models generally did
not improve the model fit and did not
appreciably alter the results.
Global estimates
The total number of patients with diabe-
tes with DR aged between 20 and 79 years
was estimated by multiplying the 2010
country-specific totals of people with di-
abetes (sourced from Diabetes Atlas) by
our pooled racial group–specific rates of
DR using the most predominant racialT
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group per country; for example, in Brazil,
where 53.7% of country is “white” (ac-
cording to 2000 census results listed in
Central Intelligence Agency, The World
Factbook) (10), our pooled Caucasian
rate was applied, and in countries where
the predominant racial group did not eas-
ily align with our limited pooled racial
groups (e.g., Melanesians in Papua New
Guinea), the overall pooled world rate
was applied.
All analyses were undertaken using
Stata Intercooled 11.1 software (StataCorp
LP, College Station, TX).
RESULTSdData were collated from
22,896 individuals from 35 studies in the
U.S., Australia, Europe, and Asia. Of these,
52% were female, 44.4% were Caucasian,
30.9% were Asian, 13.9% were Hispanic,
and 8.9%were African American. Themean
age was 58.1 years (range 3–97), median
diabetes duration was 7.9 years (interquar-
tile range [IQR] 3–16), and median HbA1c
was 8.0% (6.7–9.9%). Summary character-
istics of the diabetic participants from each
of the included studies are presented in Ta-
ble 1 and Supplementary Table 2.
Analyses of these 35 studies showed
that the overall age-standardized preva-
lence of anyDRwas 34.6% (95%CI 34.5–
34.8), PDR was 6.96% (6.87–7.04), DME
was 6.81% (6.74–6.89), and VTDR was
10.2% (10.1–10.3; data not shown).
Analyses confined to studies with similar
methodologies and rigorous outcome def-
initions showed that the age-standardized
prevalence was 35.4% (35.2–35.6) for
any DR, 7.24% (7.15–7.33) for PDR,
7.48% (7.39–7.57) for DME, and 11.7%
(11.6–11.8) for VTDR (Table 2). There
was no discernible sex difference in the
prevalence of any DR or for PDR, DME,
or VTDR. Extrapolating these prevalence
rates to the 2010 world diabetes popula-
tion, we estimate that 92.6 million (91.2–
94.0) adults had any DR, 17.2 million
(16.6–17.7) had PDR, 20.6 million (19.6–
21.6) had DME, and 28.4 million (27.6–
29.2) had VTDR.
Table 3 reports the age-standardized
prevalence of any DR by retinopathy risk
factors and other subgroups of interest.
The prevalence of any DR varied across
ethnic groups and was highest among Af-
rican Americans and lowest among
Asians. The prevalence of any DR increased
with diabetes duration (21.1 vs. 76.3%,
comparing ,10 with $20 years), HbA1c
(18.0 vs. 51.2%, comparing levels #7.0
with .9.0%), and blood pressure (30.8
vs. 39.6%, comparing blood pressure
#140/90 or .140/90), and was higher in
people with type 1 than type 2 diabetes
(77.3 vs. 25.2%). Similar relationships
were also evident in the prevalence patterns
of PDR, DME, and VTDR. There was a
trend toward a higher prevalence of
VTDR stages, but not any DR, in people
with cholesterol levels$4.0mmol/L. Anal-
ysis by year/period of fundus photography
suggests a decline in the prevalence of any
DR in the post-2000 era (Table 3).
After adjusting for known risk factors,
individuals with type 1 diabetes for $20
years were 2.7 times more likely to have
any DR (relative risk 2.69 [96% CI 2.47–
2.93]), 15 times more likely to have PDR
(15.3 [11.3–20.8]), 5 times more likely to
have DME (4.83 [3.71–6.30]), and 8.7
times more likely to have VTDR (8.69
[7.10–10.63]) compared with those with
type 2 diabetes for ,10 years (Table 4).
CONCLUSIONSdThis study pro-
vides a global estimate of the prevalence
of DR and the severe stages of DR (PDR,
DME) using individual-level data from
population-based studies worldwide. On
the basis of the data from all 35 studies on
more than 20,000 participants with di-
abetes, we estimated that among individ-
uals with diabetes, the overall prevalence
of anyDRwas 34.6%, PDRwas 7.0%,DME
was 6.8%, and VTDR was 10.2%. Analyses
confined only to studieswith similarmetho-
dologies and ophthalmologic definitions
showed that the age-standardized prev-
alence of any DR was 35.4%, PDR was
7.2%, DME was 7.4%, and VTDR was
11.7%, among individuals with diabetes.
The prevalence estimates of any DR and
VTDR were similar in men and women
and were highest in African Americans and
lowest in Asians. Prevalence rates were
substantially higher in those with type 1
diabetes and increased with duration of
diabetes, and values for HbA1c, blood pres-
sure, and cholesterol. Extrapolated to the
world diabetes population in 2010, we es-
timate that approximately 93 million may
have some DR, and 28 million may have
sight-threatening stages of DR.
The prevalence of DR has been pre-
viously reported in a number of population-
based samples (11–16). However,
prevalence estimates varied considerably
across some studies, depending on the pop-
ulation and study methodology. For exam-
ple, variable prevalence rates were reported
between populations of different ethnicities
(e.g., 32.4% in an Australian Caucasian co-
hort (14) vs. 48.0% in a Mexican American
cohort (15)) as well as between different
populations of the same ethnicity (e.g.,
35% in a U.S. Caucasian cohort (13)
and 15.3% in a more recent Australian
Caucasian cohort). More important, prev-
alence estimates for the more severe and
vision-threatening end points, such as
PDR and DME, are scarce, due to the small
numbers of these cases from individual
population-based studies. Published esti-
mates for VTDR prevalence (17–20), for
example, ranges widely, from 1.2 (17) to
32.2% (18). Our study provides the first
precise estimates for these important
clinical subgroups of DR.
The most comparable study to ours is
the pooled analysis for prevalence of DR
Table 2dAge-standardized prevalence of DR in diabetic subjects aged 20–79 years, using
studies with similar methodologies and ophthalmologic definitions
Overall
Studies
included
(n)
Total
(N)
Cases
(n)
Age-standardized
prevalence
per 100 (95% CI)
Any DR 18 12,620 4,487 35.36 (35.17–35.56)
PDR 21 13,436 957 7.24 (7.15–7.33)
DME 20 14,554 1,039 7.48 (7.39–7.57)
VTDR 18 12,710 1,481 11.72 (11.61–11.83)
Men
Any DR 18 6,252 2,263 36.27 (35.99–36.55)
PDR 21 6,376 469 7.53 (7.39–7.66)
DME 20 7,010 486 7.44 (7.30–7.57)
VTDR 18 6,051 704 11.74 (11.57–11.90)
Women
Any DR 18 6,368 2,224 34.46 (34.19–34.73)
PDR 21 7,060 488 6.98 (6.86–7.10)
DME 20 7,544 553 7.54 (7.42–7.66)
VTDR 18 6,659 777 11.70 (11.55–11.86)
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in the U.S. (6). On the basis of eight pop-
ulation studies derived from the U.S. and
Australia, an overall prevalence of 40%
for any DR and 8% for VTDR was repor-
ted (6). These estimates, however, repre-
sented findings limited to individuals
aged older than 40 years and only with
type 2 diabetes, were largely derived
from individuals of Caucasian back-
ground, did not evaluate PDR and DME
separately, and did not include studies
from Asia. Ours is the first synthesis
of individual-level data from all eligible
population-based studies worldwide
with a sufficiently large sample to allow a
more precise estimation of the prevalence
of PDR and DME.
Some of the differences in DR preva-
lence between individual studies may be
partly attributed to the differing periods
of the studies (Table 1 and Supplemen-
tary Table 3). Improvements in the
management of DR and diabetes, and in-
creased screening for diabetes, may have
led to lower DR incidence and prevalence
over time (21). Furthermore, DR suscep-
tibility may also vary among ethnic
groups. In support of the latter hy-
pothesis, a number of multiethnic cohort
studies have reported a higher DR preva-
lence among Mexican Americans than in
non-Hispanic whites (5,22,23). Others,
however, showed a similar or lower prev-
alence of DR in African Americans (18)
and Mexican Americans (24) than in
non-Hispanic whites. In some studies
(5), after adjusting for putative DR risk
factors, racial differences in the preva-
lence of DR was attributed to differing
levels of risk factors for DR, but in others,
the excess risk was unexplained (22,23,25).
Differences in socioeconomic factors, in-
cluding access to and the level of diabetes
care, and possibly genetic susceptibility
(26), may also possibly explain some of
the disparities in rates and severity of DR
in the different ethnic groups. In addition,
racial differences in the effect of DR risk
factors could also have accounted for some
of these variations (23,27). Population-
based studies incorporating host and en-
vironmental data are needed to further
clarify the effect of race and ethnicity on
DR prevalence.
We highlight several key points re-
garding the major risk factors for DR:
First, we confirm the importance of the
three major risk factors for DRddiabetes
duration (17,19,28), HbA1c (17,28–32),
and blood pressure (17,28,33)dand sug-
gest that they apply broadly across the
mild to vision-threatening stages of DR.
Second, we establish that higher total
serum cholesterol was associated with a
higher prevalence of DME, bringing clar-
ity to previously conflicting reports about
this risk factor (19). This is particularly
relevant to recent reports from trials sug-
gesting that fenofibrate, a lipid-altering
agent, may slow the development and
progression of DR (34). Fenofibrate, how-
ever, acts mostly on triglycerides, and its
effects on retinopathy in those trials were
independent of lipid levels achieved. Sta-
tins, however, did not affect DR severity
in the few studies in which this was eval-
uated, although not as a primary outcome
(35,36).
Third, we provide estimates of risk of
DR by diabetes type, in which studies in
individuals with type 1 diabetes are cur-
rently scarce. We showed that the prev-
alence of DR is substantially higher in type
1 than in type 2 diabetes (11,37), an out-
come independent of diabetes duration.
However, because we classified type of di-
abetes by age of onset (younger or older
than age 30 years), in some studies there
may be potential misclassification (e.g.,
some people with type 2 diabetes will be
younger than 30 years).
The strengths of our study include a
large sample size to determine prevalence
and risk factor associations for sight-
threatening end points (PDR, DME), the
inclusion of diverse ethnic population
samples from around the world, and
studies that had used photographic doc-
umentation of DR.
Our study has limitations. Pooling of
data from various sources introduces
many potential sources of heterogeneity
that could influence accuracy; thus, although
our estimates are highly precise, their
accuracy is unknown. Samples of different
study designs could have considerably
Table 4dAge-standardized prevalence of DR by diabetes type and duration, in diabetic
subjects aged 20–79 years, using studies with similar methodologies and ophthalmologic
definitions
DM type
DM duration
(years)
Total
(N)
Cases
(n)
Age-standardized
prevalence per
100 (95% CI)
Adjusted
relative risk*
(95% CI)
Any DR
Type 1 ,10 456 202 20.53 (18.73–22.34) 1.38 (1.19–1.59)
Type 1 10 to ,20 794 624 55.55 (51.34–59.76) 2.43 (2.19–2.69)
Type 1 20+ 1,026 914 86.22 (85.07–87.37) 2.69 (2.47–2.93)
Type 2 ,10 6,291 1,192 18.11 (17.91–18.31) 1.0
Type 2 10 to ,20 1,908 920 51.10 (49.53–52.66) 2.06 (1.91–2.23)
Type 2 20+ 726 424 52.15 (51.12–53.19) 2.45 (2.24–2.68)
PDR
Type 1 ,10 458 10 0.37 (0.31–0.43) 0.90 (0.44–1.86)
Type 1 10 to ,20 803 141 19.46 (16.38–22.53) 6.72 (4.70–9.61)
Type 1 20+ 1,052 443 40.36 (39.60–41.12) 15.33 (11.29–20.80)
Type 2 ,10 6,749 78 1.06 (1.02–1.10) 1.0
Type 2 10 to ,20 2,049 137 6.92 (6.41–7.42) 4.32 (3.16–5.91)
Type 2 20+ 788 139 15.13 (14.64–15.63) 9.79 (7.14–13.43)
DME
Type 1 ,10 399 13 0.55 (0.48–0.63) 0.59 (0.32–1.07)
Type 1 10 to ,20 587 91 12.27 (11.43–13.1) 2.50 (1.77–3.52)
Type 1 20+ 877 201 17.31 (16.83–17.8) 4.83 (3.71–6.30)
Type 2 ,10 7,286 230 3.07 (2.99–3.16) 1.0
Type 2 10 to ,20 2,255 277 11.94 (11.42–12.47) 3.22 (2.68–3.87)
Type 2 20+ 857 143 16.47 (15.93–17.01) 4.56 (3.67–5.67)
VTDR
Type 1 ,10 456 20 0.74 (0.65–0.82) 0.85 (0.52–1.38)
Type 1 10 to ,20 804 178 14.29 (13.61–14.97) 3.97 (3.08–5.12)
Type 1 20+ 1,054 518 47.2 (46.38–48.03) 8.69 (7.10–10.63)
Type 2 ,10 6,315 218 3.37 (3.28–3.47) 1.0
Type 2 10 to ,20 1,894 301 16.14 (15.41–16.87) 3.73 (3.10–4.49)
Type 2 20+ 735 209 25.95 (25.26–26.65) 6.27 (5.14–7.65)
DM, diabetes. *Adjusted for age (continuous, from 20–79 years), race (5 categories), hypertension (yes/no),
HbA1c (4 categories) and study.
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different inclusion criteria, sample selec-
tion, and study protocols. For example,
population samples could have varied con-
siderably between a cardiovascular disease
study and an eye survey, or a study on
diabetes complications.
There was also a range of methods
used in ascertaining diabetes status. Stud-
ies in which diagnosis of diabetes was
based on self-report, without confirma-
tion from blood tests, could have resulted
in an overestimate of DR prevalence rates
because those with undiagnosed diabetes
might have been erroneously excluded
from the sample denominator.
Furthermore, there were differences
in the methodologies used to detect and
diagnose DR, such as the number of eyes
photographed per subject, number of
retinal fields examined per eye, and the
grading protocols and definitions used. In
studies that did not collect data on di-
abetes type, this information was defined
on the basis of age of diagnosis, with a
cutoff at age 30 years to use as many
studies with detailed information other
than types of diabetes. Misclassification
could have occurred as a result of this
assumption. This, however, would not
have affected the overall prevalence esti-
mates but could have had a small effect of
attenuating the comparative estimates
between the type 1 and type 2 diabetes
groups. A few studies with large numbers
of participants could have influenced our
results. Finally, the absence of studies
from the Middle East, Africa, or South
America could also affect the accuracy of
our findings.
In conclusion, our current study pro-
vides the first global estimate of DR and,
more important, the two sight-threatening
end points (PDR and DME), based on a
pooled individual participant analysis of
more than 20,000 participants from 35
studies around theworld.Our study shows
that 35% of people with diabetes had some
form of DR, and that 7% had PDR, 7% had
DME, and 10% were affected by these
vision-threatening stages. We estimate that
in 2010, approximately 93 million were
affected by DR, and 28 million by VTDR.
This suggests that DR has the potential to
be the leading cause of visual impairment
and blindness worldwide. We confirmed
the importance and impact of three major
modifiable risk factorsdhyperglycemia,
hypertension, and dyslipidemiadon the
risk of all DR end points, including for
the first time, PDR andDME. These results
highlight the substantial public health
effect of diabetes, and thus, the need for
effective screening and management of
DR risk factors.
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